MDT

98.11

+1.44%↑

135.17

-3.17%↓

VEEV

216.29

-2.64%↓

HQY

84.6

-0.49%↓

NEOG

9.23

0%↓

MDT

98.11

+1.44%↑

135.17

-3.17%↓

VEEV

216.29

-2.64%↓

HQY

84.6

-0.49%↓

NEOG

9.23

0%↓

MDT

98.11

+1.44%↑

135.17

-3.17%↓

VEEV

216.29

-2.64%↓

HQY

84.6

-0.49%↓

NEOG

9.23

0%↓

MDT

98.11

+1.44%↑

135.17

-3.17%↓

VEEV

216.29

-2.64%↓

HQY

84.6

-0.49%↓

NEOG

9.23

0%↓

MDT

98.11

+1.44%↑

135.17

-3.17%↓

VEEV

216.29

-2.64%↓

HQY

84.6

-0.49%↓

NEOG

9.23

0%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

41.17 3.39

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

39.32

Max

41.68

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+35.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-44M 3.2B
Eelmine avamishind	37.78
Eelmine sulgemishind	41.17

Uudiste sentiment

By Acuity

34%

66%

107 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. jaan 2026, 16:17 UTC

Omandamised, ülevõtmised, äriostud

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

19. jaan 2026, 23:50 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

19. jaan 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

19. jaan 2026, 22:29 UTC

Market Talk

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

19. jaan 2026, 22:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

19. jaan 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

19. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. jaan 2026, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19. jaan 2026, 17:09 UTC

Market Talk

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

19. jaan 2026, 16:18 UTC

Market Talk

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

19. jaan 2026, 16:12 UTC

Market Talk

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

19. jaan 2026, 16:06 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

19. jaan 2026, 16:04 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

19. jaan 2026, 16:03 UTC

Omandamised, ülevõtmised, äriostud

LVMH, CTG Duty-Free Also Entered Into a MoU

19. jaan 2026, 16:02 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Subscription to Be Made Upon Completion of Transaction

19. jaan 2026, 16:00 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

19. jaan 2026, 16:00 UTC

Market Talk

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

19. jaan 2026, 15:58 UTC

Omandamised, ülevõtmised, äriostud

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

19. jaan 2026, 15:57 UTC

Omandamised, ülevõtmised, äriostud

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

19. jaan 2026, 15:57 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Proceeds of Transaction Will Be Paid in Cash

19. jaan 2026, 15:56 UTC

Omandamised, ülevõtmised, äriostud

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

19. jaan 2026, 15:53 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

19. jaan 2026, 15:52 UTC

Omandamised, ülevõtmised, äriostud

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

19. jaan 2026, 15:51 UTC

Omandamised, ülevõtmised, äriostud

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

19. jaan 2026, 15:39 UTC

Market Talk

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

19. jaan 2026, 15:37 UTC

Market Talk

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

35.29% tõus

12 kuu keskmine prognoos

Keskmine 54.09 USD 35.29%

Kõrge 62 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

107 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.